EUVIMEDEUVIMED entdecken
Korrektur

Larocca A, Bonello F, Gaidano G, et al. Dose/schedule-adjusted Rd-R vs continuous Rd for elderly, intermediate-fit patients with newly diagnosed multiple myeloma. Blood. 2021;137(22):3027-3036.

Blood · 2023

DOI: 10.1182/blood.2022018970 ↗

Kurz gefasst

Korrektur in der Zeitschrift Blood, 2023. Hauptthemen laut MEDLINE: Multiple Myeloma.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Multiple MyelomaHumansAgedLenalidomideThalidomideAntineoplastic Combined Chemotherapy ProtocolsDexamethasoneTreatment Outcome

Substanzen

LenalidomideThalidomideDexamethasone

Zitieren

APA

(2023). Larocca A, Bonello F, Gaidano G, et al. Dose/schedule-adjusted Rd-R vs continuous Rd for elderly, intermediate-fit patients with newly diagnosed multiple myeloma. Blood. 2021;137(22):3027-3036. Blood. https://doi.org/10.1182/blood.2022018970

Vancouver

Larocca A, Bonello F, Gaidano G, et al. Dose/schedule-adjusted Rd-R vs continuous Rd for elderly, intermediate-fit patients with newly diagnosed multiple myeloma. Blood. 2021;137(22):3027-3036. Blood. 2023. doi:10.1182/blood.2022018970

BibTeX
@article{euvimed2023,
  title = {Larocca A, Bonello F, Gaidano G, et al. Dose/schedule-adjusted Rd-R vs continuous Rd for elderly, intermediate-fit patients with newly diagnosed multiple myeloma. Blood. 2021;137(22):3027-3036},
  journal = {Blood},
  year = {2023},
  doi = {10.1182/blood.2022018970}
}
Kostenlos starten →